Pelubiprofen Oral Formulation Particle Size Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral pharmaceutical formulations of pelubiprofen face challenges in achieving a high dissolution rate and stability, as smaller particle sizes improve dissolution but compromise stability due to increased reactivity with additives.
Innovation Solution
An oral pharmaceutical formulation of pelubiprofen with a mean particle size ranging from 1 to 30 μm, combined with specific additives such as lactose, hydroxypropyl cellulose, carboxymethyl cellulose calcium, and magnesium stearate, enhances dissolution rate and stability without generating excessive related compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If the particle size of pelubiprofen is reduced to improve dissolution rate, then the dissolution rate increases, but the stability decreases due to increased reactivity with additives
Solution Approach 1:
The patent applies parameter changes by optimizing the particle size of pelubiprofen to a specific range (1-30 μm, preferably 3-10 μm) to achieve the best balance between dissolution rate and stability. This quantitative parameter optimization resolves the contradiction by identifying the critical threshold where benefits maximize while drawbacks are controlled.
Solution Approach 2:
The patent applies local quality by selecting specific types of additives (lactose, hydroxypropyl cellulose, carboxymethyl cellulose calcium, magnesium stearate) that are compatible with fine particles. Different additives serve different local functions: lactose as filler, hydroxypropyl cellulose and carboxymethyl cellulose calcium as binders, and magnesium stearate as lubricant, each chosen to work harmoniously with the 1-30 μm pelubiprofen particles.
2Productivity
If the particle size of pelubiprofen is reduced to increase surface area, then the dissolution rate improves, but the generation of related compounds increases
Solution Approach 1:
The patent controls the particle size parameter within 1-30 μm to optimize dissolution while limiting the generation of related compounds. This parameter optimization prevents excessive surface area that would lead to disproportionate degradation and harmful byproduct formation.
Solution Approach 2:
The patent introduces specific additives as intermediaries between pelubiprofen and the environment. These additives (lactose, hydroxypropyl cellulose, carboxymethyl cellulose calcium, magnesium stearate) act as protective mediators that reduce direct exposure to degrading factors while maintaining dissolution efficiency, thereby reducing harmful related compound generation.
3Speed
If injection formulations are used to achieve rapid pharmacological effects, then the onset of action is rapid, but the administration flexibility is limited
Solution Approach 1:
The patent transforms the oral formulation parameters to match injection-like performance by reducing pelubiprofen particle size to 1-30 μm. This parameter change in the oral route achieves rapid dissolution and absorption comparable to injections, providing both speed and administration flexibility.
Solution Approach 2:
The patent extracts the key advantage of injections (rapid onset) and transfers it to an oral formulation through particle size reduction. By isolating and applying only the essential feature of rapid delivery without the injection administration requirement, the patent achieves both speed and flexibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves high bioavailability and rapid pharmacological effects while maintaining stability, with minimal generation of related compounds, even under severe storage conditions.
Implementation Method 1
improving the dissolution rate of oral pharmaceutical formulations may be achieved by 1) milling particles of active ingredients into small sizes
Data Source
AI summary
Disclosed is an oral pharmaceutical formulation of pelubiprofen which is improved in dissolution rate and stability. As a result of an improvement in the dissolution rate of pelubiprofen, the oral pharmaceutical formulation can show high bioavailability and thus exert pharmacological effects thereof rapidly. It also can be stored with high stability as a result of the minimal generation of related compounds.